LPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

LPL Financial LLC grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 15.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 425,090 shares of the company's stock after acquiring an additional 57,305 shares during the quarter. LPL Financial LLC owned 0.11% of Recursion Pharmaceuticals worth $2,249,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Recursion Pharmaceuticals by 15.5% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 76,730 shares of the company's stock valued at $406,000 after purchasing an additional 10,272 shares during the period. ARK Investment Management LLC grew its position in shares of Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after purchasing an additional 2,469,104 shares during the period. Cetera Investment Advisers boosted its position in Recursion Pharmaceuticals by 22.6% during the 1st quarter. Cetera Investment Advisers now owns 75,788 shares of the company's stock worth $401,000 after acquiring an additional 13,955 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $57,000. Finally, IFP Advisors Inc boosted its position in Recursion Pharmaceuticals by 33.6% during the 1st quarter. IFP Advisors Inc now owns 15,808 shares of the company's stock worth $84,000 after acquiring an additional 3,977 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

RXRX traded up $0.16 during trading hours on Friday, reaching $4.94. The company's stock had a trading volume of 19,864,289 shares, compared to its average volume of 19,922,800. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company's 50-day moving average is $5.46 and its 200-day moving average is $5.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58. The firm has a market cap of $2.14 billion, a PE ratio of -2.78 and a beta of 0.93.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The business had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm's revenue was up 33.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) EPS. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $7.00.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at $3,688,447.44. This trade represents a 5.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.43% of the stock is owned by insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.